Summary & Overview
HCPCS C9079: Injection of Evinacumab-dgnb, 5 mg
HCPCS Level II code C9079 denotes a billed unit for the injection of evinacumab-dgnb at a 5 mg dose. This code matters nationally as it captures administration of a specialty biologic therapy used in specific lipid-lowering or rare disease treatment pathways; accurate coding affects claims processing, coverage determinations, and specialty pharmacy coordination. Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn what the code represents clinically and operationally, how major payers typically approach coverage and prior authorization for specialty injectables, and what benchmarks and policy considerations influence billing and reimbursement for high-cost biologics. The publication outlines typical sites of service for administration, common billing practices tied to unitized drug codes, and areas where policy updates or payer guidelines commonly impact payment (for example, billing documentation, infusion versus pharmacy billing distinctions, and medical benefit versus pharmacy benefit coverage). Data not available in the input is noted where payer-specific rates, taxonomies, or linked diagnosis codes would normally be summarized.
Billing Code Overview
HCPCS Level II code C9079 describes injection, evinacumab-dgnb, 5 mg. This code represents a billed unit for the administration of evinacumab-dgnb, an intravenous or injectable monoclonal antibody formulation dosed in 5 mg increments. The service type is drug administration / pharmacologic therapy. The typical site of service is an outpatient infusion center, physician office, or hospital outpatient department, where parenteral biologic therapies are administered and billed separately from facility services.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with homozygous familial hypercholesterolemia (HoFH) or refractory severe hypercholesterolemia who has not achieved adequate LDL-C reduction with maximally tolerated lipid-lowering therapy. The patient presents to an outpatient infusion center or hospital outpatient clinic for administration of an intravenous monoclonal antibody therapy, C9079 (injection, evinacumab-dgnb, 5 mg). Pre-infusion evaluation includes review of prior lipid panels, current medications, allergy history, and vital signs. An infusion nurse or pharmacist prepares the appropriate dose based on the patient’s weight and the product vial size; the medication is administered via peripheral IV or existing central venous access. Monitoring during and for a period after the infusion includes vital signs and assessment for infusion-related reactions such as hypersensitivity. Documentation includes indication, dose administered, lot number, route, site, any pre-medication (e.g., antihistamine, antipyretic), and observations during and after infusion. Typical sites of service are outpatient infusion centers, ambulatory clinics, hospital outpatient departments, and occasionally inpatient settings for patients requiring closer monitoring. The likely clinical workflow: order verification by pharmacy, pre-medication as indicated, IV line placement, infusion under nursing supervision, post-infusion observation, and documentation and billing using C9079 with appropriate modifier(s) reflecting circumstances of service.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|